Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of deadlines, meetings, and Skype calls has, of course, returned, although at a slightly slower pace due to observance of a holiday in some places on this side of the pond. Nonetheless, we are forging ahead with a cup or three of stimulation — the season’s pumpkin spice is our choice this morning. On that note, here are some tidbits to get you going. Hope all goes well today and do keep in touch…

A U.S. bankruptcy judge temporarily halted scores of lawsuits against Purdue Pharma and its owners, the Sackler family, The Washington Post writes. Extending that relief to the Sacklers, who have not filed for bankruptcy protection, is “extraordinary” but appropriate in this case, Judge Robert Drain said. During the three-week reprieve, Purdue Pharma agreed to address one of the key concerns — access to more information about the Sacklers’ finances — raised by state attorneys general who objected to including the family in the temporary injunction.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.